

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 November 2024 (14.11.2024)



(10) International Publication Number
WO 2024/231440 A1

(51) International Patent Classification:
C07K 16/12 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2024/062700

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(22) International Filing Date:
08 May 2024 (08.05.2024)

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/501,036 09 May 2023 (09.05.2023) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventors: **BRILSFORD, Wayne**; AstraZeneca AB, SE-151 85 Södertälje (SE). **LAMBIASE, Giulia**; AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB). **DIGIANDOMENICO, Antonio**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **SOU, Si Nga**; MedImmune Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Association 813, Eastbrook House, Shaftesbury Road, CAMBRIDGE Cambridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: BISPECIFIC ANTI-PSEUDOMONAS ANTIBODIES WITH MODIFIED FC REGIONS AND METHODS OF USE THEREOF

(57) Abstract: The present disclosure relates to a bispecific antibody that specifically binds to *Pseudomonas aeruginosa* PcrV protein and Psl exopolysaccharide and that comprises a modified Fc region. Such bispecific antibodies can, for example, have increased half-life and decreased aggregation in the manufacturing process without a decreased potency against *Pseudomonas*, as compared to bispecific antibodies without the modified Fc region.

WO 2024/231440 A1